Dietary Supplements for Menopause Transition — What the Evidence Actually Says

If you walk down the supplement aisle looking for menopause relief, you’ll find dozens of products making quiet promises. Black cohosh for hot flashes. Soy isoflavones for night sweats. Red clover, evening primrose oil, DHEA — the shelf runs deep, and the marketing runs deeper.

Here’s what the shelf won’t tell you.

The National Center for Complementary and Integrative Health — part of the NIH — reviewed the evidence on dietary supplements for menopause symptoms and reached a blunt conclusion: “none has clearly been shown to be helpful.” Not one.

And yet, surveys suggest more than half of menopausal women in the US and Europe use over-the-counter products for symptom relief. That tension — between what the evidence says and what millions of women are reaching for — is what this article is about.

The scale of the problem, and the search for answers

#

Roughly 1.3 million women in the US enter menopause each year, typically between ages 45 and 56, according to NIH estimates. Hot flashes, night sweats, sleep disruption, mood changes — the symptoms are real and, for many women, severe enough to affect daily life.

Hormone replacement therapy is the most effective treatment available. In November 2025, the FDA announced it would remove the “black box” warning from HRT products, a move that’s reopening the conversation about what safe, effective menopause treatment looks like. But many women have reasons to seek non-hormonal options — personal preference, contraindications, a history of hormone-sensitive cancer — and the supplement industry is more than ready to meet that demand.

So the real question — the one that should be flashing above every supplement aisle — is whether the products on offer actually deliver.

What the major guidelines say

#

Three major reviews published over the past decade have shaped the evidence picture on menopause supplements, and none of them is encouraging.

The NCCIH position — that no dietary supplement has clearly been shown to be helpful — anchors the conservative end of the evidence picture. It’s not that every supplement has been disproven. It’s that, for most of the ingredients in menopause products, the research simply isn’t strong enough to draw conclusions. (And by “strong enough” I don’t mean merely imperfect — I mean most ingredients have two studies or fewer.)

The Menopause Society’s 2023 nonhormone therapy position statement, the most recent guideline-level document, moved most herbal and supplement options into the “not recommended” category. Soy foods and soy extracts? Not recommended. Black cohosh? Not recommended. General herbal remedies? Not recommended. The evidence behind these products is what the Society classifies as Level I-II — and, look, in guideline-speak that’s not “needs more research,” that’s “not good enough to recommend.”

And the NIH Office of Dietary Supplements, in a May 2026 research digest, flagged a structural problem: more than 80 ingredients have been studied for menopause symptoms, but over half of them appear in two or fewer studies. That’s not an evidence base — that’s a collection of pilot data.

What the guidelines do recommend, at Level I — the strongest evidence tier — might surprise readers who’ve been focused on the supplement aisle. Cognitive behavioral therapy and clinical hypnosis are the non-drug approaches with the best evidence for reducing hot flash bother and improving menopause-related quality of life. The Menopause Society also gives Level I recommendations to prescription non-hormonal medications including SSRIs, SNRIs, gabapentin, and fezolinetant (Veozah), an NK3 receptor antagonist approved by the FDA in 2023 — but those fall outside the scope of this article.

The supplement-by-supplement evidence

#

What follows is not a ranking. Ranking would imply a level of clinical endorsement the evidence doesn’t support — and honestly, you can flip through the studies yourself and land exactly where the guidelines land, which is uncomfortable territory for a site that covers supplements. Instead, it’s a walk through what the research says — and, more importantly, what it doesn’t say — about the most commonly used menopause supplements.

Black cohosh

#

Black cohosh is the most recognizable menopause supplement on the market. It’s been used for over 50 years in Germany for menopausal complaints, and its traditional use by Native Americans for musculoskeletal pain, fever, and menstrual irregularities stretches back much further.

The evidence, however, is thin. The largest independent review — a 2012 Cochrane analysis of 16 clinical trials involving more than 2,000 women — found there wasn’t enough consistent evidence to say whether black cohosh works for menopause symptoms. A major NIH-funded trial called the HALT study, with 351 women followed for 12 months, found no significant difference between black cohosh and placebo. The Cochrane review calculated a mean difference of 0.07 hot flashes per day — a number so close to zero that the 95% confidence interval (-0.43 to 0.56) crossed well into negative territory.

The safety concern is not subtle. Products labeled as black cohosh have been linked to more than 50 cases of clinically apparent liver injury worldwide, including acute liver failure requiring transplant and, in some cases, death. The NIH’s LiverTox database assigns black cohosh a likelihood score of A — the highest category, meaning it is a well-established cause of liver injury, even though the exact ingredient responsible remains unclear. Australia requires a liver warning on black cohosh products. The US Pharmacopeia recommends cautionary labeling advising users to stop immediately if they develop jaundice, dark urine, or abdominal pain.

There’s a complicating factor worth understanding. Clinical trials involving more than 1,200 patients found no liver enzyme elevations — yet real-world pharmacovigilance data has identified dozens of serious cases. The discrepancy may stem from product quality: DNA testing has found that some commercial “black cohosh” products contain Chinese Actaea species rather than authentic North American black cohosh. It’s not yet clear whether genuine black cohosh itself is hepatotoxic, or whether the problem is mislabeling and adulteration.

Beyond the liver risk, black cohosh has 348 known drug interactions, including 9 classified as major. In vitro studies suggest it may interfere with tamoxifen and some chemotherapy drugs — a serious concern for breast cancer survivors, who are a significant consumer demographic for menopause supplements.

A 2025 clinical trial (96 women, 90 days) found that a combination of black cohosh, soy isoflavones, and SDG lignans produced a significant reduction in menopause rating scale scores (-48% vs placebo). This is interesting — but it’s one small study, it used a combination protocol rather than black cohosh alone, and it hasn’t been replicated.

What to know: Black cohosh isn’t supported by current evidence as an effective menopause treatment, and it carries a documented risk of serious liver injury. Anyone using it should tell their doctor and stop immediately if they develop jaundice, dark urine, or unexplained abdominal pain.

Soy isoflavones

#

Soy foods — tofu, tempeh, edamame, soy milk — have been consumed for centuries in Asian diets. Historically, hot flash reporting has been lower in Asian populations, though confounding by diet, culture, genetics, and reporting bias makes causal attribution difficult.

Concentrated soy isoflavone supplements are a different proposition from dietary soy. A 2016 JAMA meta-analysis of 62 randomized controlled trials involving 6,653 women found that phytoestrogen supplements produced a modest reduction in hot flash frequency — roughly one fewer hot flash per day (-1.31, 95% CI -2.02 to -0.61). There was also a small improvement in vaginal dryness scores. Night sweats showed no significant benefit.

The quality evidence is weak. Of the 62 trials in the JAMA analysis, 74% had high risk of bias in three or more quality domains. That makes the finding directional rather than definitive. The Menopause Society categorizes soy foods and soy extracts as “not recommended” with Level II evidence.

An important biological wrinkle explains why some women report benefit while most trials show mixed results. Soy isoflavones — specifically daidzein — must be converted to a more active form called equol by gut bacteria to exert their strongest estrogenic effects. Only about 30 to 50 percent of Western women are “equol producers.” The rest lack the necessary gut microbes. This means that, biologically, soy isoflavones may genuinely work for a subset of women — but if you don’t know whether you’re an equol producer, and most women don’t, you’re taking a supplement that may do nothing for you.

Safety considerations: The long-term safety of concentrated phytoestrogen supplements taken for years hasn’t been established. NCCIH explicitly flags this as an unknown. Women with a history of estrogen-receptor-positive breast cancer should approach phytoestrogen supplements with particular caution — the evidence on hormonal impact is mixed, and NCCIH recommends caution. Soy may also interfere with thyroid hormone absorption, so women on levothyroxine or other thyroid medications should separate dosing by several hours.

What to know: Soy isoflavones may offer a modest reduction in hot flash frequency — about one fewer per day — but the evidence is inconsistent, most studies have quality problems, and only some women (equol producers) are biologically positioned to benefit. Dietary soy is safer and better-studied than concentrated supplements.

Red clover

#

Red clover contains isoflavones similar to those in soy — biochanin A and formononetin, which the body converts to genistein and daidzein. The evidence for hot flash relief is inconsistent.

A 12-month randomized controlled trial (89 women), comparing black cohosh, red clover, placebo, and HRT, is instructive for what it reveals about placebo effects in menopause research. Red clover produced a 57 percent reduction in symptoms — but placebo produced 63 percent. HRT, by comparison, produced 94 percent. The trial found no significant difference between red clover and placebo for hot flash reduction. There was one signal worth noting: red clover showed a significant reduction in anxiety, possibly related to activity at the ER-beta receptor.

What to know: The best-quality evidence doesn’t support red clover as an effective treatment for hot flashes. The anxiety finding is preliminary.

Evening primrose oil, dong quai, ginseng

#

These three are worth grouping together because they share a common evidence profile: they’ve been studied and found ineffective for menopause symptoms. This is different from black cohosh or soy, where the evidence is merely insufficient. Here, the negative finding is reasonably clear.

Evening primrose oil (EPO) contains gamma-linolenic acid, which may influence prostaglandin synthesis — a plausible mechanism — but clinical trials haven’t found it effective for hot flashes. Both the Low Dog 2005 comprehensive review in the American Journal of Medicine and the NCCIH reach the same conclusion. The Mayo Clinic lists EPO under “no scientific proof” for menopause symptoms. Safety note: EPO may increase bleeding risk when taken with anticoagulants like warfarin or apixaban.

Dong quai (Angelica sinensis), used in Traditional Chinese Medicine for gynecological conditions, hasn’t been shown effective for hot flashes in clinical trials. It contains coumarin derivatives that can significantly potentiate warfarin and increase bleeding risk. It may also increase sun sensitivity.

Ginseng (Panax ginseng), used as an adaptogen in TCM, hasn’t been proven effective for menopause symptoms in the available clinical evidence, per both the Low Dog review and NCCIH.

What to know: These supplements have been tested and found ineffective for menopause symptoms. Dong quai carries a specific, serious drug interaction risk with blood thinners.

DHEA

#

DHEA is a hormonal prohormone — not a botanical — that the body converts to estrogen and testosterone. The mechanism is well-established, but the clinical evidence for menopause symptoms is not.

Topical DHEA may provide modest improvement in vaginal dryness and pain with intercourse. Oral DHEA hasn’t been consistently shown to help with hot flashes, sexual function, cognition, or overall wellbeing, per Mayo Clinic and NCCIH assessments.

The safety concern is hormone-related. Because DHEA converts to estrogen and testosterone in the body, high doses or long-term use may increase the risk of hormone-sensitive cancers including breast and endometrial cancer. Women with a history of these cancers, or other hormone-sensitive conditions, shouldn’t use DHEA. Side effects can include acne, hair loss, facial hair growth, voice deepening, and mood changes.

What to know: Topical DHEA may help with vaginal symptoms. Oral DHEA hasn’t been proven effective for general menopause symptoms and carries hormone-sensitive cancer concerns.

A note on kava

#

Kava shouldn’t appear in any discussion of “natural” menopause relief without a prominent safety warning. The risk of severe, potentially fatal liver damage is well-documented. The NCCIH warns against kava use. Multiple countries have banned or restricted kava products. It occasionally appears in menopause combination products despite this risk. It shouldn’t be used.

Calcium and vitamin D — a separate conversation

#

Calcium and vitamin D belong in a different category from the botanicals discussed above. They’re nutrient supplements relevant to bone health during and after menopause — not symptom relief — and they come with their own evolving evidence picture.

The recommended calcium intake for postmenopausal women is 1,200 mg per day, ideally from food sources. Supplements can help fill gaps but should be discussed with a doctor, not assumed safe because they’re “just vitamins.”

The US Preventive Services Task Force, in a 2024 draft recommendation, advised against routine vitamin D supplementation — with or without calcium — for primary fracture prevention in community-dwelling postmenopausal women. This is a Grade D recommendation, meaning the USPSTF recommends against the service because there is moderate or high certainty it has no net benefit or that harms outweigh benefits.

And the harms aren’t theoretical. Long-term follow-up of the Women’s Health Initiative, tracking women for a median of 22.3 years, found that those who took calcium and vitamin D supplements had a 6 percent higher risk of death from cardiovascular disease than those who took placebo. Calcium supplements (as distinct from dietary calcium) are also associated with increased kidney stone risk, along with the more common side effects of constipation and bloating.

So here’s the thing: the USPSTF position isn’t universally accepted. It conflicts with guidance from the International Menopause Society and some osteoporosis organizations. This is an area of active debate, and postmenopausal women with elevated fracture risk or diagnosed bone loss may have different clinical considerations. The point isn’t that calcium and vitamin D are dangerous — it’s that they aren’t the risk-free, universally recommended interventions many women assume them to be.

What to know: Calcium needs increase after menopause, but food sources are preferred. Routine vitamin D supplementation for fracture prevention is no longer recommended by the USPSTF. The WHI data on cardiovascular risk is worth discussing with a doctor before starting supplements.

What the guidelines recommend instead

#

If supplements are mostly “not recommended” by the Menopause Society, what non-drug approaches are?

Cognitive behavioral therapy and clinical hypnosis hold Level I evidence — the strongest recommendation tier — for reducing hot flash bother and improving menopause-related quality of life. CBT, in this context, typically involves learning to reframe the experience of hot flashes and reduce the distress they cause, rather than trying to eliminate the physiological event itself. Clinical hypnosis involves guided relaxation and focused attention techniques that have been shown in randomized trials to reduce both the frequency and severity of hot flashes.

These approaches require trained practitioners and commitment — they aren’t as easy as swallowing a capsule (which, honestly, is most of the supplement industry’s entire business model). But they are evidence-backed in ways that no supplement currently is.

For women seeking non-hormonal prescription options, fezolinetant (Veozah) — an NK3 receptor antagonist approved by the FDA in 2023 — represents a newer pathway. It targets the brain’s thermoregulatory center rather than supplementing hormones. NAMS gives it a Level I recommendation. It requires liver function monitoring and a prescription, so it falls outside the self-treatment model that draws many women to supplements — but its existence is worth knowing about.

How to think about menopause supplements

#

Several context points matter for anyone trying to make sense of this picture.

The placebo effect is unusually large in menopause research. The black cohosh and red clover trial mentioned earlier — the one where placebo outperformed both botanicals — found a 63 percent placebo response rate at 12 months. The study authors explicitly warn that future trials must account for placebo effects exceeding 60 percent. This matters because smaller, unblinded, or short-duration studies that report positive results may be capturing placebo response rather than pharmacological effect.

Dietary supplements are not FDA-approved. Under the Dietary Supplement Health and Education Act of 1994, supplements don’t require pre-market safety or efficacy testing. Manufacturers can’t claim their products diagnose, treat, cure, or prevent any disease — but they can make “structure/function” claims that sound close. Every supplement label must carry the disclaimer: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Most consumers don’t read this language — and I mean, have you ever squinted at the fine print on a supplement bottle? — and many don’t know what it means even when they do notice it.

“Natural” does not mean safe. The NCCIH is explicit on this point: many dietary supplements come from natural sources, but “natural” doesn’t always mean safe. Black cohosh, kava, and dong quai all carry serious documented risks despite being botanical products.

Product quality varies widely. DNA testing has found substantial mislabeling in commercial black cohosh products. A manufacturer’s use of terms like “standardized” or “certified” doesn’t guarantee product quality or consistency. The active ingredients in most botanicals are unknown, making standardization to a meaningful potency effectively impossible.

Most women don’t tell their doctors. Research suggests that roughly 70 percent of women around menopause use botanical or dietary supplements, but fewer than one in ten can describe what specific health benefit they expect — and 70 percent don’t disclose supplement use to their healthcare providers. This matters because supplements can interact with prescribed medications, affect liver function, and complicate diagnosis when symptoms arise.

Questions to ask your doctor

#

If you’re using supplements, considering them, or dealing with disruptive menopause symptoms, here are the specific questions worth bringing to a healthcare visit — and yes, writing these down before you go through the clinic door actually helps.

Ask whether your liver function should be tested, especially if you’re using or thinking about black cohosh. Ask whether any of your current medications interact with the supplements you’re taking — blood thinners, thyroid medications, tamoxifen, and other hormonal therapies are the big ones to flag. Given your personal and family history, ask whether there’s any reason you should avoid phytoestrogens or DHEA — this matters for hormone-sensitive cancer risk. Ask whether you’re getting enough calcium from your diet, or whether a supplement would actually make sense for you. Ask whether your symptoms could be caused by something other than menopause — thyroid disorders, depression, sleep apnea, and autoimmune conditions can all mimic menopause symptoms, and it’s worth ruling those out. And ask what non-hormonal, non-supplement options — like CBT or clinical hypnosis — are actually available to you, because these are the evidence-backed approaches that most supplement marketing conveniently ignores.

Bottom line

#

Here’s the short version.

The gap between what menopause supplements promise and what the evidence supports is wide. The NIH’s central finding — that no dietary supplement has clearly been shown to be helpful for menopause symptoms — should be the starting point for any consumer decision in this category.

And look, this doesn’t mean every supplement is useless or dangerous. It means the evidence base isn’t strong enough to recommend any of them with confidence. Black cohosh carries a documented liver risk that requires prominent disclosure. Soy isoflavones may work modestly for a subset of women but the studies are inconsistent and most have quality concerns. Evening primrose oil, dong quai, and ginseng have been studied and found ineffective. DHEA involves hormonal risks that deserve careful discussion with a doctor. Calcium and vitamin D, while important nutrients, aren’t risk-free and should be approached through food where possible.

The most evidence-backed non-drug approaches — cognitive behavioral therapy and clinical hypnosis — aren’t supplements, and they’re harder to access than a bottle from the supplement aisle. But for women seeking alternatives to medication that are actually supported by evidence, they represent a more grounded starting point than any of the products currently commanding shelf space.